These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2967323)

  • 1. Practical applications of decision analysis.
    Nettleman MD
    Infect Control Hosp Epidemiol; 1988 May; 9(5):214-8. PubMed ID: 2967323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is it cost-beneficial to screen adolescent males for chlamydia?
    Alexander ER
    Am J Public Health; 1990 May; 80(5):531-2. PubMed ID: 2109543
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infection in women.
    Gupta M; Hernon M; Gokhale R; Ghosh AK
    Sex Transm Infect; 2002 Feb; 78(1):76. PubMed ID: 11872877
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approaches.
    Postma MJ; Welte R; van den Hoek JA; Morré SA
    Sex Transm Infect; 2002 Feb; 78(1):73-4. PubMed ID: 11872873
    [No Abstract]   [Full Text] [Related]  

  • 5. [Towards screening for Chlamydia trachomatis].
    Kolmos HJ
    Ugeskr Laeger; 1997 Aug; 159(34):5104-5. PubMed ID: 9297316
    [No Abstract]   [Full Text] [Related]  

  • 6. Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing.
    Morré SA; Welte R; Postma MJ
    Sex Transm Infect; 2002 Feb; 78(1):74-5. PubMed ID: 11872874
    [No Abstract]   [Full Text] [Related]  

  • 7. An economic assessment of pre-vaccination screening for hepatitis A and B.
    Jacobs RJ; Saab S; Meyerhoff AS; Koff RS
    Public Health Rep; 2003; 118(6):550-8. PubMed ID: 14563912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States.
    Ditkowsky J; Shah KH; Hammerschlag MR; Kohlhoff S; Smith-Norowitz TA
    BMC Infect Dis; 2017 Feb; 17(1):155. PubMed ID: 28214469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of antenatal hepatitis B screening and vaccination of infants.
    Thomas IL
    Aust N Z J Obstet Gynaecol; 1990 Nov; 30(4):331-5. PubMed ID: 2150586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
    Ruitenberg EN
    Ned Tijdschr Geneeskd; 1999 May; 143(19):1012. PubMed ID: 10368724
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus.
    Arevalo JA; Washington AE
    JAMA; 1988 Jan; 259(3):365-9. PubMed ID: 2961895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Screening for asymptomatic Chlamydia trachomatis infection: cost-effectiveness favorable at a minimum prevalence rate of 3% or more].
    Habets PC
    Ned Tijdschr Geneeskd; 2001 Mar; 145(10):499-501. PubMed ID: 11268916
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of hepatitis A/B vaccination in the private sector.
    Jacobs RJ; Meyerhoff AS
    Sex Transm Dis; 2005 Aug; 32(8):465. PubMed ID: 16041246
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-benefit analysis of hepatitis-B vaccination. A computerized decision model for Spain.
    Jönsson B; Horisberger B; Bruguera M; Matter L
    Int J Technol Assess Health Care; 1991; 7(3):379-402. PubMed ID: 1834602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economic methodology illustrated with recent work on Chlamydia screening: the concept of extended dominance.
    Postma MJ; de Vries R; Welte R; Edmunds WJ
    Sex Transm Infect; 2008 Apr; 84(2):152-4. PubMed ID: 18077610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for Chlamydia trachomatis in adolescent males: a cost-based decision analysis.
    Randolph AG; Washington AE
    Am J Public Health; 1990 May; 80(5):545-50. PubMed ID: 2109544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of widespread screening for Chlamydia trachomatis.
    Postma MJ; Welte R; Morré SA
    Expert Opin Pharmacother; 2002 Oct; 3(10):1443-50. PubMed ID: 12387690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sexuality and health: the hidden costs of screening for Chlamydia trachomatis.
    Duncan B; Hart G
    BMJ; 1999 Apr; 318(7188):931-3. PubMed ID: 10102865
    [No Abstract]   [Full Text] [Related]  

  • 19. Chlamydia trachomatis: common misperceptions and misunderstandings.
    Stevens-Simon C; Sheeder J
    J Pediatr Adolesc Gynecol; 2005 Aug; 18(4):231-43. PubMed ID: 16171726
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-benefit analysis of hepatitis B vaccination.
    Padayachee GN
    S Afr Med J; 1991 Jan; 79(1):2-3. PubMed ID: 1824729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.